Cited 32 times since 2000 (1.3 per year) source: EuropePMC Annals of oncology : official journal of the European Society for Medical Oncology, Volume 11, Issue 1, 1 1 2000, Pages 109-112 A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Giaccone G, Smit EF, van Meerbeeck JP, Splinter T, Golding RP, Pinedo HM, Laan D, van Tinteren H, Postmus PE
Thirty patients with chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.
